Future Risks and Uncertainties

... KRAS patients and 58 months for mutated KRAS patients. Median OS for mutated ... This document is solely provided for informational purposes only and is based on ... Apr 24, 2025 ... KRAS wild-type (absence of mutations in exons 2, 3, and 4) and NRAS ... informational purposes. Clinical data such as case reports ... Jul 18, 2016 ... ... research areas include Structural Biology and. Biochemistry, RAS Assays, Biology of Mutant KRAS. Cell Lines, Pathway Analysis, Cell Surface ... This presentation is for informational purposes only and may not be ... A2 KRAS G12V T Cell Engagers Displayed Functional Activity in in vitro & in ... ... KRAS inhibitors. It works by blocking the action of the abnormal protein that ... information is provided for informational purposes only. The entire ... 5 days ago ... Revolution Medicines Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the ... Aug 9, 2022 ... Visit www.iaslc.org for more information. About the WCLC: The WCLC is the world's largest meeting dedicated to lung cancer and other thoracic ... May 3, 2024 ... Hotspots Tested: BRAF (NM_004333) exon 15; KRAS (NM_004985) exons 2, 3, 4; NRAS (NM_002524) exons 2, 3, 4. See Additional Technical Information ... Sep 10, 2023 ... The findings suggest durable clinical activity of adagrasib for KRAS G12C-mutated NSCLC. “The study data demonstrates compelling results, ... Dec 8, 2021 ... ... K-Ras. In the ... Any health information on this website is strictly for informational purposes and is not intended as medical advice.